MyFinsight
Home
Blog
About
Proceeds from sale of
common stock and...
$431,315K
Proceeds from exercise of
stock options
$5,231K
Proceeds from issuance of
common stock under...
$66K
(65.00%↑ Y/Y)
Net cash provided by
(used in) financing...
$410,209K
(87564.61%↑ Y/Y)
Canceled cashflow
$26,403K
Increase (decrease) in
cash, cash...
$60,296K
(165.41%↑ Y/Y)
Canceled cashflow
$349,913K
Transaction costs paid
pursuant to sale of common...
$26,403K
Sales and maturities
of investments
$23,876K
Accrued expenses and
other current...
$6,625K
(2168.84%↑ Y/Y)
Change in fair value of
contingent consideration
$6,574K
Stock-based compensation
$5,305K
(-10.97%↓ Y/Y)
Accounts payable
$2,991K
(43.59%↑ Y/Y)
Change in fair value of
derivative liability
-$1,010K
(-146.98%↓ Y/Y)
Deferred taxes
$17K
(-29.17%↓ Y/Y)
Depreciation and
amortization
$17K
(-93.68%↓ Y/Y)
Net cash used in
investing activities
-$329,925K
(-365.60%↓ Y/Y)
Net cash used in
operating activities
-$19,988K
(4.12%↑ Y/Y)
Canceled cashflow
$23,876K
Canceled cashflow
$22,539K
Purchases of investments
$353,801K
(399.30%↑ Y/Y)
Net loss
-$36,358K
(-7.21%↓ Y/Y)
Contingent consideration
paid pursuant to...
$4,813K
Prepaid expenses and
other current assets
$922K
(138.07%↑ Y/Y)
Accretion of
available-for-sale investments,...
$418K
(186.30%↑ Y/Y)
Lease liability, net
-$16K
(-214.29%↓ Y/Y)
Back
Back
Cash Flow
Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX)
source: myfinsight.com